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Novel cardioprotective and regenerative 
therapies in acute myocardial infarction: 
a review of recent and ongoing clinical trials
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Following the original large-scale randomized trials of aspirin and β-blockade, there have 
been a number of major advances in pharmacological and mechanical treatments for 
acute myocardial infarction. Despite this progress, myocardial infarction remains a major 
global cause of mortality and morbidity, driving a quest for novel treatments in this area. 
As the understanding of mitochondrial dynamics and the pathophysiology of reperfusion 
injury has evolved, the last three decades have seen advances in ischemic conditioning, 
pharmacological and metabolic cardioprotection, as well as biological and stem-cell 
therapies. The aim of this review is to provide a synopsis of adjunctive cardioprotective and 
regenerative therapies currently undergoing or entering early clinical trials in the treatment 
of patients with acute myocardial infarction.
First draft submitted: 20 May 2016; Accepted for publication: 24 August 2016; Published 
online: 28 October 2016
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Ischemic heart disease remains a leading cause of death worldwide, responsible for an estimated 
17.5 million deaths in 2012 [1]. The persistence of ischemic heart disease as a major cause of global 
mortality and morbidity despite major therapeutic advances in this area, along with an evolv-
ing understanding of the reperfusion injury itself, has led to a focus on novel therapies to limit 
myocardial injury and facilitate myocardial recovery following acute myocardial infarction. With 
numerous strategies proposed, this review will provide a synopsis of novel therapies currently in 
research development or undergoing clinical trials, in addition to considering future directions for 
exploration.
Current treatments for acute myocardial infarction
The current management of patients presenting with acute myocardial infarction focuses on anti-
platelet and antithrombotic treatment coupled with invasive assessment of coronary anatomy with 
a view to revascularization where appropriate [2–4]. Pharmacological therapies such as β-blockade, 
statins and inhibitors of the renin–angiotensin–aldosterone axis improve cardiac remodeling and 
subsequent cardiac events including myocardial ischemia and the development of heart failure [5]. 
Despite these advances and the establishment of clinical standards and national campaigns to pro-
mote guideline-driven management of patients with acute myocardial infarction, ischemic heart 
disease remains a major global cause of death and disability. The search for more effective treatments 
to limit myocardial injury following abrupt coronary artery occlusion continues. Major areas of 
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Figure 1. Overview of novel therapeutic strategies. 
RIPC: Remote ischemic preconditioning; PICSO: Pressure-controlled intermittent coronary sinus occlusion. 
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endeavor include the prevention of reperfusion 
injury by mechanical or pharmacological means, 
regenerative therapies for the myocardium and 
metabolic strategies including cooling (Figure 1). 
This review will summarize major progress in 
these areas to date.
Methods
A literature search was performed by two authors 
using PubMed and ClinicalTrials.gov using the 
following key words: ‘novel therapies’, ‘regenera-
tive therapies’, ‘myocardial infarction’, ‘reperfu-
sion injury’, ‘ischemic conditioning’, ‘pharma-
cological conditioning’ and ‘cardioprotection’ 
to identify relevant ongoing or recent clinical 
trials and systematic reviews on cardioprotective 
and regenerative therapies for acute myocardial 
infarction undergoing current or recent clinical 
trial [6]. We limited our search to papers pub-
lished between 1950 and 30 April 2016. Any 
papers identified through the bibliographies of 
the original articles were subsequently screened.
Reperfusion injury & ischemic 
preconditioning
While restoration of myocardial perfusion 
remains the cornerstone of treatment for acute 
coronary occlusion, reducing the insult caused 
by the ensuing reperfusion injury has attracted 
significant interest in recent years. Myocardial 
reperfusion injury describes the damage to or 
death of vulnerable myocytes that occurs as a 
result of restoration of blood flow and has been 
seen following thrombolysis, percutaneous coro-
nary intervention (PCI), coronary artery bypass 
grafting and cardiac transplantation [7]. Central 
to the pathophysiology of reperfusion injury is 
the mitochondrion, where overproduction of 
reactive oxygen species (driven further by neu-
trophil activation) and dysfunctional calcium 
handling leads to altered myocardial metabo-
lism as well as microvascular and endothelial 
dysfunction [1,8,9].
Mitochondrial dynamics in cell death
Our understanding of mitochondrial dynamics 
has advanced significantly in recent years, nota-
bly of their role in the regulation of cell death. 
Independent of mode, cell death is intrinsically 
linked to mitochondrial dynamics through regu-
lation of mitochondrial membrane permeabiliza-
tion which, once induced, initiates a rapid and 
irreversible cascade of enzymatic interactions 
that ultimately leads to organized cell destruc-
tion [10]. Mitochondrial membrane permeabi-
lization is dependent on a complex interplay 
between numerous regulatory mechanisms 
at mitochondrial membranes; the proposed 
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mechanism by which remote ischemia condi-
tioning prevents opening of the mitochondrial 
permeability transition pore (mPTP) within the 
inner mitochondrial membrane [11]. Recognition 
of mitochondrial membrane permeabilization 
as the decisive event in myocardial cell death 
by ischemia reperfusion injury [12], in addition 
to most pathophysiology of cell death, has led 
to inhibition of this process becoming a major 
therapeutic target in this field.
Cardioprotective therapies
●● Ischemia conditioning
Ischemic preconditioning
The phenomenon of ischemic precondition-
ing, administration of periods of short-lived 
ischemia prior to a more prolonged ischemic 
insult, was first demonstrated almost 30 years 
ago by Murry et al. [12] who observed a dramatic 
reduction in infarct size in canine hearts follow-
ing administration of local, transient myocardial 
ischemia prior to total occlusion of the circum-
flex artery. Ischemic preconditioning (IPC) has 
subsequently been shown to have a beneficial 
effect in animal and human studies, in the heart 
as well as other organs [13]. The precondition-
ing stimulus can be delivered either locally or 
remotely to the target organ at risk of infarction 
with numerous molecular signaling pathways 
implicated, although the exact mechanisms have 
yet to be established [14,15].
The invasive nature and temporal require-
ments of the local preconditioning stimulus rela-
tive to the ischemia-reperfusion insult have lim-
ited the applicability of local IPC in the setting 
of acute myocardial infarction. Consequently, 
attention has focused on remote IPC (rIPC), 
where tissues other than the heart are exposed 
to ischemia protocols, with subsequent signaling 
pathways resulting in a reduction in myocardial 
reperfusion injury. This phenomenon was first 
demonstrated within the canine coronary arte-
rial tree where transient occlusion of circumflex 
artery prior to induction of ischemia reperfusion 
injury in the left anterior descending artery in 
canine models resulted in a significant reduction 
in infarct size (6 vs 16% in controls) [16]. The 
most convincing evidence of a benefit with IPC 
in man arises from trials in patients undergoing 
cardiac surgery. A recent meta-analysis of IPC 
in patients undergoing cardiac surgery included 
22 eligible trials with a total of 933 patients [17]. 
In the majority of studies, the IPC stimulus con-
sisted of cycles of brief aortic cross-clamping, 
although three trials utilized coronary artery 
occlusion. Overall, IPC was associated with a 
significant reduction in ventricular arrhythmia, 
inotropic requirement and length of stay in 
intensive care unit [17].
For obvious reasons, cross-clamping of the 
aorta would be impractical in patients presenting 
with acute myocardial infarction. As a surrogate, 
transient limb ischemia induced by inflation of 
a blood pressure cuff to suprasystolic pressure 
has also been shown to be sufficient to induce 
myocardial protection in patients exposed to 
ischemia-reperfusion injury. Three recent meta-
analyses of rIPC using transient limb ischemia 
as the stimulus [18–20] (including five studies 
[n = 731], nine studies [n = 1119] and 11 studies 
[n = 1713], respectively) confirmed an observed 
reduction in procedural cardiac biomarker 
release in patients undergoing predominantly 
elective PCI with rIPC compared with control. 
It remains unclear whether a reduction in car-
diac marker release will translate into a clinically 
significant reduction in major adverse cardiac 
and cerebrovascular events (MACCE) [21]. These 
meta-analyses were published prior to the pub-
lication of the large clinical outcome ERICCA 
trial [22] that included 1612 patients undergoing 
coronary artery bypass surgery in 30 centers. 
Patients were randomized to rIPC (4 × 5 min-
inflations and deflations of a blood pressure cuff 
on the upper arm) or a sham preconditioning 
procedure. The primary end point was a com-
posite of death from cardiovascular causes, non-
fatal myocardial infarction, coronary revascu-
larization or stroke, at 12 months. Remote IPC 
did not reduce the primary outcome (hazard 
ratio [HR]: 0.95; 95% CI: 0.79–1.15) or any 
of the secondary outcomes. Indeed, rIPC did 
not reduce perioperative myocardial injury, 
suggesting alternative approaches to modulate 
mitochondrial membrane permeabilization are 
necessary in the setting of cardiac surgery.
The effects of rIPC have been examined in 
two modest sized clinical trials of patients with 
ST-segment elevation myocardial infarction 
(STEMI). Bøtker et al. [23] randomized 333 
STEMI patients to four cycles of upper arm 
rIPC prior to PCI or PCI alone, with investi-
gator blinding only, observing a small but sig-
nificant improvement in myocardial salvage 
index in addition to left ventricular ejection 
fraction in patients treated with rIPC (47% 
rIPC cohort vs 43% control), which was most 
evident in patients with anterior myocardial 
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infarction. Although these changes were no 
longer evident at 30 days, all-cause mortality 
and the composite end point of death, myocar-
dial infarction, readmission for heart failure and 
ischemic stroke/transient ischemic attack were 
lower in the rIPC group compared with con-
trol (HR: 0.32; 95% CI: 0.12–0.88; p = 0.027 
and HR: 0.49; 95% CI: 0.27–0.89; p = 0.018, 
respectively) after 3.8 years of follow-up. Using 
a similar design, White et al. [24] randomized 
197 patients to either four cycles of upper arm 
rIPC prior to coronary angioplasty or sham, 
observing a 27% reduction in infarct size using 
cardiac MRI with rIPC. Although promising, 
these results require to be confirmed in a larger 
clinical trial before rIPC can be recommended 
as mainstream treatment for STEMI. To address 
this, two large multicenter collaborative trials 
of CONDI-2/EPIC-PPCI (NCT01857414, 
NCT02342522) are ongoing with results antici-
pated in 2017 [6]. Additionally, the RIC-STEMI 
trial (NCT02313961) [6] will add to the existing 
data, aiming for enrollment of over 400 and ran-
domizing to rIPC or control, with end points of 
left ventricular ejection fraction and infarct size 
as well as MACCE at 12 months.
Ischemic postconditioning
Ischemic postconditioning, or slow reperfusion, 
was first demonstrated by Zhao et al. in 2003 
utilizing a canine artery ligation model, where 
administration of three cycles of 30 s of reper-
fusion and reocclusion immediately following 
prolonged coronary artery occlusion was found 
to be as effective as ischemic preconditioning at 
attenuating myocardial reperfusion injury [25]. 
The therapeutic window for administration of 
the postconditioning stimulus following the 
ischemic stimulus appears narrow [26] and, as 
with IPC, the mPTP appears to be common to 
both mechanisms of action [27].
Attempts to translate the experimental ben-
efits of postconditioning into the clinical arena 
have yielded mixed results. An early prospective 
multicenter trial randomized patients with acute 
STEMI to primary PCI alone versus primary 
PCI followed by intermittent coronary artery 
occlusions (postconditioning) [26]. The authors 
observed a 36% reduction in infarct size at 
72 h by biomarker assay and improvement of 
blush grade (p < 0.05), although there were no 
significant improvements in ECG parameters. 
While these findings have been repeated in other 
studies [28–32], a similar number have failed to 
demonstrate a reduction in infarct size [33–36] 
with one study reporting reduced myocardial 
salvage with ischemic postconditioning [37]. The 
meta-analysis by Abdelnoor et al. found no net 
cardioprotective effect from postconditioning, 
with small sample sizes biasing outcomes of left 
ventricular ejection fraction [38]. Methodological 
bias in the form of absence of adequate sham and 
blinding is present in a minority of the studies 
but almost all studies contribute bias through 
small sample size and patient heterogeneity. 
Larger trial data are awaited from the ongoing 
DANAMI 3 trial [39].
●● Pharmacological conditioning
A multitude of pharmacological approaches have 
been developed to reduce the adverse impact of 
reperfusion injury. A drug which can be admin-
istered intravenously to effectively confer pos-
tischemic conditioning offers an attractively 
practical therapeutic option in comparison to 
invasive ischemic preconditioning and biological 
approaches. Preclinical data have highlighted the 
importance of oxidative stress and chemokine 
expression as potential therapeutic targets for 
pharmacological agents in STEMI [40]. We pre-
sent an overview of the relevant agents in recent 
or ongoing clinical trials.
Cyclosporine A
The immunosuppressant drug cyclosporine is 
well established in clinical use in many inflam-
matory conditions and post-transplantation. 
Following on from experimental data demon-
strating that cyclosporine A inhibits opening 
of the mPTP, a small randomized pilot study 
(n = 58) examined the benefits of cyclosporine 
A in patients with STEMI [41]. Treatment with 
cyclosporine A was associated with a 40% reduc-
tion in serum creatine kinase, but not troponin, 
at 5 days and in a subgroup (n = 27), a 20% 
reduction in infarct size at 6 months. In con-
trast, the recently published, multicenter, dou-
ble-blinded, randomized CIRCUS trial enrolled 
almost 800 patients with STEMI and observed 
no significant difference in left ventricular ejec-
tion fraction, adverse remodeling or clinical 
outcome at 12 months with intravenous cyclo-
sporine A administered prior to PCI, compared 
with placebo [42]. Similarly, in the recently pub-
lished multicenter CYCLE trial [43] (n = 410), 
pretreatment with cyclosporine A had no effect 
on ST-segment resolution at 60 min, cardiac 
biomarker release, left ventricular remodeling or 
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clinical events out to 6 months. A third smaller 
randomized controlled trial, CAPRI [44], assess-
ing the effect of cyclosporine A in patients with 
STEMI undergoing PCI will be reported in 
2018.
Exenatide
Exenatide is a glucagon-like peptide-1 analog 
used in the treatment of diabetes mellitus [45]. 
In addition to its hypoglycemic properties, it 
is thought to have potential benefits in reduc-
ing infarct size in myocardial reperfusion 
injury [46–48]. In a study by Lønborg et al. [49], 
infusion of exenatide initiated prior to primary 
PCI for STEMI was associated with a 30% 
relative reduction in infarct size where PCI 
was performed within 132 min from presenta-
tion. The smaller EXAMI study [50] followed 
this but examined a higher dose of exenatide. 
It established safety and efficacy at higher dose, 
but found no change in infarct size or clinical 
end points. In a further randomized, placebo 
controlled trial (n = 58) of patients with STEMI, 
subcutaneous exenatide administered at the time 
of primary PCI was associated with a signifi-
cant reduction in infarct size as assessed by bio-
marker release and cardiac MRI [51]. A Phase II 
study of exenatide in patients with STEMI, the 
EMPRES trial (NCT01938235 [6]), is ongoing.
Adenosine
Adenosine has been shown to induce car-
dioprotective effects in the setting of myocar-
dial ischemia through a variety of proposed 
mechanisms including regulation of heart 
rate, blood pressure and vasodilatation [52]. 
The AMISTAD [53] pilot trial randomized 
237 patients presenting within 6 h of onset of 
STEMI to receive a systemic intravenous infu-
sion of either adenosine or placebo, in addition 
to reperfusion therapy. Compared with placebo, 
there was a 33% relative reduction in infarct size 
with adenosine and this benefit was greatest in 
patients with anterior infarction. The larger 
Phase III AMISTAD II [54] trial randomized 
2118 patients to one of two dosing regimens of 
adenosine or placebo. Despite a reduction in 
infarct size with the higher dose of adenosine, 
this failed to translate into a reduction in clini-
cal end points, including the composite primary 
end point of new onset congestive heart failure 
or death within 6 months. More recently, tri-
als of intracoronary adenosine before and after 
stent deployment have failed to demonstrate any 
improvement in myocardial salvage index [55] or 
perfusion with adenosine [56]. The multicenter 
REFLO-STEMI [57] trial randomized patients 
with STEMI presenting within 6 h to undergo 
PCI with either adjunctive intracoronary adeno-
sine or intracoronary sodium nitroprusside or 
PCI alone (n = 247) and found no difference 
in infarct size, microvascular obstruction or 
major adverse cardiovascular events at 6 months 
between treatment groups.
Nitric oxide signaling
Preclinical and early clinical data have dem-
onstrated that nitric oxide has cardioprotec-
tive potential by reducing myocardial oxygen 
demand, increasing coronary blood flow and 
reducing spasm [58]. The NOMI [59] study 
randomized 250 patients with acute STEMI 
to inhaled nitric oxide or placebo. While 
there was no effect on infarct size, there was a 
trend to improved recovery of left ventricular 
function with nitric oxide which became sig-
nificant at 4 months. Using a different donor, 
sodium nitroprusside, the multicenter REFLO-
STEMI [57] trial failed to demonstrate any ben-
efit compared with placebo in patients with 
STEMI undergoing primary PCI. The results 
of a second randomized placebo-controlled 
Phase II trial of sodium nitroprusside in STEMI, 
NITRITE-AMI [60], are awaited.
Modulating mitochondrial function
As the importance of molecular signaling at the 
mitochondrial membrane in ischemia reperfu-
sion injury has become clearer, research has been 
directed toward directly regulating mitochon-
drial function. A number of promising candi-
date drugs targeting mitochondrial function 
have emerged from preclinical work to undergo 
Phase I and II clinical trials. Protein kinase C 
isoenzyme, widely considered essential in the 
mechanism of reperfusion preconditioning, was 
investigated in the PROTECTION-AMI [61] 
study, which enrolled 1176 patients with STEMI 
and randomized them to one of three doses of 
delcasertib (a specific protein kinase C inhibi-
tor) or placebo. Despite the encouraging experi-
mental data, no effects on extent of myocardial 
injury or clinical end points were observed with 
delcasertib. A compound that delays mPTP 
opening, TRO40303, reduced myocardial 
infarct size in preclinical models but has failed 
to live up to expectations in early clinical trials. 
The randomized controlled MITOCARE [62] 
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study evaluated the efficacy of intracoronary 
TRO40303 in 163 STEMI patients and found 
no effect on infarct size or left ventricular func-
tion at 1 month. Similarly, MTP-131 (bendavia), 
a compound that both scavenges reactive oxy-
gen species and inhibits opening of the mPTP, 
was evaluated in the Phase II EMBRACE-
STEMI [63] trial. Enrolling 297 patients with 
STEMI, EMBRACE-STEMI reported no sig-
nificant change in infarct size or left ventricu-
lar function with administration of MTP-131. 
Failure to translate encouraging preclinical data 
to clinical trials with these novel agents has been 
suggested to relate, at least in part, to unfamili-
arity with appropriate dose regimens and lack 
of sufficient statistical power to clarify trends in 
clinical end points [62,64].
Atrial natriuretic peptide
Atrial natriuretic peptide is a powerful endog-
enous vasodilator. Kitakaze et al. randomized 
569 patients with STEMI undergoing primary 
PCI to either atrial natriuretic peptide or pla-
cebo administered as an infusion over 3 days 
and reported a 14.7% reduction in infarct size 
by serum biomarker and an increase in left ven-
tricular ejection fraction at 2–8 weeks postin-
farct that was still present at 6–12 months [65]. 
However, atrial natriuretic peptide has been used 
widely in Japan for treatment of acute heart fail-
ure [66] and, in a recent retrospective analysis, a 
significantly increased in-hospital mortality was 
identified in patients treated with the drug com-
pared with those who were not [67]. It has also 
been associated with increased requirement for 
renal replacement therapy in patients undergo-
ing cardiovascular surgery [68]. These findings 
mitigate the initial promise of atrial natriuretic 
peptide in this context and call for larger studies 
to better characterize its risk–benefit profile in 
acute myocardial infarction.
Other novel agents
The SOLSTICE [69] study investigated los-
mapimod, a novel inhibitor of the stress-acti-
vated kinase p38 MAPK. Despite no significant 
change in serum biomarkers of infarct size, 
there was an increase in left ventricular ejection 
fraction and decrease in end systolic and dias-
tolic pressures both at 3–5 days and 12 weeks 
postinfarct in a proportion of patients undergo-
ing cardiac MRI. Following this, the ongoing 
multicenter LATITUDE-TIMI 60 [70] trial aims 
to enroll >25,000 patients to assess the efficacy 
and safety of p38 MAPK inhibition with los-
mapimod in both STEMI and non-STEMI with 
results expected in December 2018.
The function of the myocardial sodium–
hydrogen exchanger in intracellular acid-
base regulation has also been implicated 
in reperfusion injury. Disappointingly, fol-
lowing promise in experimental models, 
the sodium–hydrogen exchanger inhibitors eni-
poride and cariporide failed to demonstrate any 
cardioprotective results although there were no 
concerning adverse effects [71,72]. More recently, 
a novel sodium–hydrogen exchanger inhibitor 
(TY-51924) was trialed in patients with STEMI. 
While there was no overall improvement in myo-
cardial salvage index with TY-51924, in a post-
hoc analysis, subjects with a large area of myocar-
dium at risk and no anterograde flow did appear 
to gain some benefit [73]. There is scope for larger 
studies to clarify the role of sodium–hydrogen 
exchanger inhibition in cardioprotection.
The compound, FX06, an endogenous pep-
tide derived from human fibrin, has been inves-
tigated in the treatment of STEMI on account 
of its anti-inflammatory properties [58]. The 
proof-of-concept FIRE [74] study established no 
effect on infarct size assessed by late gadolinium 
enhancement at 5 days postinfarction, although 
a reduction in the size of necrotic core zone on 
cardiac MRI was observed with FX06.
Bioabsorbable alginate IK-5001 is a polysac-
charide polymer produced from brown seaweed 
that, in the presence of excess ionized calcium 
present in infarcted myocardium, assembles to 
form a flexible gel structurally resembling extra-
cellular matrix [75]. In theory, this may provide 
temporary support to the infarct zone and in 
an experimental model, reverse left ventricular 
remodeling postinfarct. Intracoronary IK-5001 
injection is currently undergoing investigation in 
patients with STEMI in the PRESERVATION 1 
study (NCT01226563 [6]). Publication of the 
data is expected in 2020 but preliminary data 
presented at the European Society of Cardiology 
Congress 2015 have not indicated any positive 
effect on adverse left ventricular remodeling 
compared with placebo at 6 months [76].
●● Metabolic & mechanical strategies
Therapeutic hypothermia
Early clinical work has indicated that induc-
tion of early mild therapeutic hypothermia 
may be associated with a reduction in infarct 
size in patients with acute STEMI [77,78]. The 
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early establishment of hypothermia would seem 
to be a key determinant of the degree of car-
dioprotection, with maximum protection in 
animal models occurring when hypothermia 
was established prior to ischemic stimulus [79]. 
Various methods of inducing hypothermia have 
been explored, with the need to find a balance 
between rapid induction of hypothermia and an 
acceptable level of invasiveness to be clinically 
useful in the context of concurrent reperfusion 
therapies. The COOL-MI and ICE-IT trials 
evaluated the combination of endovascular 
cooling with intravenous cold saline prior to 
reperfusion therapy in patients with STEMI 
and reported no overall reduction in infarct size 
at 30 days [80]. However, in a post hoc analysis, 
there was a suggestion of benefit in patients with 
anterior myocardial infarction [81]. One of the 
major concerns with this strategy has been the 
delay to reperfusion as a result of the cooling 
process. However, utilizing the same methods, 
the pilot study RAPID MI-ICE [82] randomized 
20 acute myocardial infarction patients to 3 h 
of therapeutic hypothermia or control, success-
fully achieving hypothermia (<35°C) prior to 
reperfusion in 100% of patients (n = 18) with no 
delay to reperfusion. In this pilot study, cooling 
was associated with a 37% reduction in infarct 
size. The larger CHILL-MI [83] study followed 
this with a shorter period of hypothermia (1 h) 
and randomized 120 patients with STEMI to 
hypothermia by either rapid cold saline infusion 
and endovascular cooling or standard care. The 
investigators reported no significant reduction 
in infarct size, but did observe lower incidence 
of heart failure at 45 days in anterior STEMIs 
(3% hypothermia vs 14% control), with poten-
tial inference of a positive effect in this group. 
In contrast to endovascular cooling, the mul-
ticenter VELOCITY [84] trial used automated 
peritoneal lavage to induce therapeutic hypo-
thermia, with disappointing results. Fifty-four 
patients were randomized to 3 h of peritoneal 
hypothermia or control. No improvement in 
infarct size was demonstrated, with an increase 
in both major adverse cardiovascular events and 
stent thrombosis in the treatment group.
Hyperoxemia
The preclinical finding that hyperbaric oxygen 
delivery can reduce myocardial ischemia-rep-
erfusion injury led to its clinical investigation 
in AMIHOT I [85]. Hyperoxemia was induced 
and maintained with an extracorporeal aqueous 
oxygen circuit. Again, while no significant 
impact on size of infarct was seen, there was 
a suggestion of benefit in the anterior STEMI 
subgroup. AMIHOT II [86] followed this, using 
Bayesian hierarchical modeling to include some 
of the AMIHOT I data, and reported a reduc-
tion in infarct size by 6.5%, more marked at 10% 
in the subgroup with left ventricular ejection 
fraction <40%. The international multicenter 
DETO2X-AMI trial ([6], NCT01787110), ran-
domizing 6600 patients with STEMI to inhaled 
oxygen therapy or room air for 6–12 h postin-
farction, aims to clarify the role of hyperoxemia 
in cardioprotection. This follows on from the 
AVOID trial [87], a multicenter prospective ran-
domized controlled trial of 638 patients with 
STEMI, which reported a possible deleterious 
effect of inhaled oxygen in the form of increased 
early myocardial injury when administered in 
the absence of hypoxia.
Coronary sinus occlusion
Pressure-controlled intermittent coronary sinus 
occlusion (PICSO) aims to improve myocar-
dial microvascular perfusion following PCI in 
patients with anterior STEMI. In theory, by 
occluding the coronary sinus, arterial wedge 
pressure will rise, increasing perfusion pressure 
in the infarcted territory. Evaluated in a small 
safety and feasibility study of 30 patients with 
STEMI, PICSO had no effect on myocardial 
recovery or infarct size evaluated by cardiac 
MRI when compared with matched historical 
controls [88]. Although there were no major 
safety issues, logistical difficulties permitted 
only 12 of 30 patients to undergo the speci-
fied 90 min of therapy. When the analysis 
was restricted to those patients who actually 
received the treatment, infarct size reduction 
from 2–5 days to 4 months was greater for 
patients successfully treated with PICSO com-
pared with matched controls (41.6 ± 8.2% vs 
27.7 ± 9.9%, respectively; p = 0.04). Further 
work is required to evaluate the feasibility and 
efficacy of PICSO in acute myocardial infarc-
tion before any meaningful conclusions can be 
reached.
Regenerative therapies
●● Biological therapies
Regenerative medicine has generated substan-
tial interest in recent years. The prospect of 
developing novel treatments for acute myo-
cardial infarction that stimulate angiogenesis, 
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promote myocardial regeneration and prevent 
left ventricular dysfunction is highly attractive. 
Multiple strategies have been proposed ranging 
from the mobilization of endogenous progeni-
tor cells through the administration of targeted 
growth factors to engraftment of autologous or 
allogeneic cells [89]. The structural and func-
tional complexity of myocardium means that 
simply transplanting stem cells into the infarct 
zone is unlikely to work in isolation, integra-
tion of engrafted tissue with existing myocardial 
tissue being critical to the restoration of func-
tional myocardium [89]. However, in the face of 
an incomplete understanding of the complex 
mechanisms governing stem cell and growth fac-
tor regulation and interaction, there has been lit-
tle consensus on the optimal cell type and route 
of administration and research approaches have 
varied hugely. Here, we focus on cell therapies 
and growth factors that have been evaluated in 
clinical trials.
Cell therapies
The regenerative potential of multiple cell types 
and sources is being evaluated. These range from 
pluripotent stem-cell populations capable of dif-
ferentiation to multiple cardiac cell types, often 
derived from embryonic stem cells or induced 
pluripotent stem cells, to adult stem cells includ-
ing cardiac progenitor cells (CPC), adipose-
derived stem cells and bone marrow-derived cells 
(BMCs). These cells differ widely in their origin, 
proliferative potential and degree of maturity. 
The safety and effectiveness of some of these cell 
therapies have been studied in clinical trials while 
others await translation to clinical research [90].
Early studies have assessed the effectiveness 
of adult stem cells (BMC and adipose-derived 
cells) that are more readily accessible, but less 
likely to contribute directly to myocardial 
regeneration. Use of autologous cells avoids the 
need for immune suppression and circumvents 
ethical concerns, but these adult stem cells are 
lineage-committed and less able to differentiate 
into cardiac cells compared with pluripotent 
stem cells that can form functional cardiomy-
ocytes, smooth muscle cells and endothelial 
cells [91]. While CPC populations have been 
isolated from the adult heart during cardiac 
surgery, and these cells may be more likely 
than BMC to regenerate the myocardium, 
therapeutic use will require cell banking and 
transplantation of allogeneic cells in to patients 
with acute myocardial infarction.
Bone marrow cells as a source of endothelial 
progenitor cells
Over a decade ago, Asahara et al. defined a 
putative endothelial progenitor cell, isolated 
from blood mononuclear cells and thought to 
arise from the bone marrow, with the potential 
to home to sites of vascular injury and directly 
contribute to vascular repair and neovasculariza-
tion [92–94]. BMC therapies have been evaluated 
in patients with acute myocardial infarction pri-
marily as they are thought to contain endothelial 
progenitor cells. Indeed both populations con-
tain cells expressing endothelial surface markers 
and give risk to cells with an endothelial mor-
phology when cultured under angiogenic con-
ditions [95]. Our understanding of endothelial 
progenitor cell biology has evolved since these 
original descriptions and two different popu-
lations have been isolated and characterized. 
Early outgrowth cells or colony forming unit-
endothelial progenitor cells are hematopoietic 
in origin, express leukocyte markers, but do not 
undergo prolonged proliferation in culture [95]. 
Despite evidence of indirect paracrine proangio-
genic properties, early outgrowth cells do not 
directly contribute to vascular repair and are 
no longer considered progeny of a circulating 
endothelial progenitor cell. In contrast, endothe-
lial outgrowth cells have a typical endothelial 
morphology and phenotype, lack expression 
of hematopoietic and leukocyte antigens, can 
proliferate in culture for prolonged periods and 
from perfusing vessels in vivo, but uncertainty 
remains as to the origin of their progeny [95].
A myriad of small Phase I and II clinical trials 
of cell-based therapies in patients with STEMI, 
with differences in the cell types used and the 
mode of delivery, have yielded mixed results. 
Much of the clinical work to date in cell thera-
pies for myocardial infarction has focused on 
the intracoronary delivery of BMC therapies, 
but despite a large amount of endeavor, the 
promise of regenerative cell-based therapies in 
the setting of acute myocardial infarction has 
yet to be realized. Meta-analyses of BMC trials 
performed up to 2008 consistently confirmed a 
small but statistically significant increase in left 
ventricular ejection fraction (3.66%; 95% CI: 
1.93–5.4%, largest analysis [96]) of cell therapy 
delivered 7 days postinfarction [97,98]. Of the tri-
als reporting beneficial effects on left ventricular 
ejection fraction, most enrolled <50 patients to 
treatment [99,100] and one did not include a sham 
control and therefore was not double blind [101]. 
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Figure 2. Mean ejection fraction effect size by number of discrepancies in 
autologous bone marrow stem cell trials’ reports.  
Adapted with permission from [108] © BMJ Publishing Group Limited (2014).
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The REPAIR-AMI trial is the largest study to 
date (n = 204) and, employing a double-blinded 
sham-controlled design [102] demonstrated a 
trend toward improvement in left ventricular 
ejection fraction with cell therapy as assessed by 
cardiac MRI. The treatment effect was marginal 
but statistically significant after an adjustment 
for differences in the left ventricular ejection 
fraction at baseline assessed by left ventricular 
angiography. Subsequent studies using cardiac 
MRI as the sole method for defining the primary 
outcome failed to demonstrate an effect of cell 
therapy on left ventricular ejection fraction [103–
106]. A random effects meta-analysis of 22 rand-
omized controlled trials of intracoronary BMC 
therapy following acute myocardial infarction 
published between 2002 and 2013 [107] observed 
a small but significant increase in left ventricular 
ejection fraction of 2.1% compared with con-
trol and an associated reduction in infarct size. 
However, this benefit was lost when the meta-
analysis was restricted to studies using cardiac 
MRI to define left ventricular ejection fraction. 
Cell therapy was not associated with any effect 
on MACCE at 6 months.
In an effort to explain the marked hetero-
geneity in reported outcomes with autologous 
BMC therapies in patients with acute myocar-
dial infarction, the DAMASCENE [108] inves-
tigators undertook a weighted-regression meta-
analysis of 49 trials, looking for discrepancies 
in study design, execution, analysis and inter-
pretation. A positive correlation was observed 
between the number of discrepancies and the 
reported augmentation in left ventricular ejec-
tion fraction with the greatest effect on left ven-
tricular ejection fraction seen in trials with no 
sham control procedure (Figure 2). Perhaps most 
notably, the five trials with no discrepancies 
reported no effect on left ventricular ejection 
fraction from BMC therapies. It seems likely 
that the lack of benefit of these therapies is in 
part explained by the absence of true endothe-
lial progenitor cells in bone marrow. It may be 
that other cell populations may enhance cardiac 
function or promote angiogenesis through other 
mechanisms. It is critical that we understand 
these mechanisms before embarking on further 
clinical trials of undifferentiated or mixed cell 
populations.
Mesenchymal stem cells
Mesenchymal stem cells, initially described in 
bone marrow, have wide differentiation potential 
and broad tissue distribution [109]. Phase I and 
II studies have established safety and feasibil-
ity [110,111], observing a tendency to improvement 
in left ventricular ejection fraction and reduc-
tion in ventricular dysrhythmia. Ixmyelocel-T 
is a cell therapy developed from autologous 
bone marrow where the final expanded prod-
uct is enriched for macrophages and CD90+ 
mesenchymal stem cells [112]. In a recent multi-
center, double-blinded, placebo-controlled trial, 
126 patients with ischemic-dilated cardiomyo-
pathy were randomized to receive transcatheter 
intra-myocardial Ixmyelocel-T or placebo, with a 
composite primary end point of all-cause mortal-
ity, cardiovascular admissions or attendances for 
heart failure. While the investigators reported a 
significant reduction in the primary end point 
in patients receiving Ixmyelocel-T, surprisingly 
this was not associated with improvements in left 
ventricular volume or ejection fraction.
Cardiac progenitor cells
CPCs are resident in adult cardiac tissue and 
have been evaluated in patients with ischemic 
cardiomyopathy. There is no consensus as to 
the optimal method to define these cells, but 
the surface expression of c-kit (stem-cell fac-
tor) provides an opportunity to isolate puta-
tive CPC populations from the human heart. 
The SCIPIO trial [113] enrolled 33 patients who 
underwent isolation and expansion of c-kit+ 
cells from the right atrial appendage harvested 
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Table 1. Key trials and meta-analyses of novel therapeutic strategies in myocardial infarction.
Novel 
therapy
Study (year)/
meta-analysis
Number 
enrolled, 
study design
Intervention 
for STEMI
End points Outcomes/notes Ref.
Cardioprotective therapies 
rIPC Bøtker et al. 
(2010)
333, 
single-center 
RCT
rIPC (4 × 5 
min cycles) vs 
standard care
MSI at 30 days  Small significant increase in MSI and 
EF
[23]
White et al. 
(2015)
197 rIPC (4 × 5 min 
cycles) vs sham 
pre-PPCI
MI size by CMR at 3–6 days Reduction in MI size in rIPC arm [24]
Hausenloy 
DJ et al. (2015) 
ERICCA
1612, 
multicenter 
RCT
rIPC (4 × 5 min 
cycles) vs sham 
pre-PPCI
Cardiovascular death, 
nonfatal MI, PCI/CABG or 
stroke (1 year)
No significant difference in primary 
end point
[22]
IPost Abdelnoor et al. 
(2014)
21, RCTs 
random-
effects meta-
analysis
Various regimes 
of CA occlusion
MI size by CMR, serum 
biomarkers, ECG changes
 No significant cardioprotection 
Possible benefit on HF incidence
[38]
Cyclosporine 
A
Cung TT et al. 
CIRCUS
791, 
multicenter, 
double-
blinded RCT
iv. cyclosporine 
pre-PPCI vs 
placebo
Death, worsening HF or 
admission, adverse LV 
remodeling
No significant difference in primary 
end point
[42]
Ottani F et al. 
(2016) CYCLE
410, 
multicenter 
RCT
iv. cyclosporine 
pre-PPCI vs 
standard care
≥70% ST resolution (60 
min), serum biomarkers, 
LV remodeling, clinical end 
points to 6 months
No significant difference in any end 
point
[43]
Exenatide Woo JS et al. 
(2013)
58, placebo-
controlled 
RCT
SC exenatide at 
PPCI vs placebo
MI size and LV function 
by CMR (1 month), serum 
biomarkers (3–6 days)
Significant improvement in MI size 
and EF 
18 patients in treatment arm
[51]
Adenosine Ross AM et al. 
(2005) AMISTAD-
II
2118, double-
blind, 
placebo-
controlled 
RCT
iv. adenosine 
(two dose 
regimes) vs 
placebo
New HF or hospitalization 
at 6 months
No reduction in primary end point 
despite reduced MI size at higher 
dose
[54]
Adenosine/
nitroprusside
Nazir SA et al. 
(2015) REFLO-
STEMI
247, 
multicenter 
RCT
IC adenosine or 
SNP at PPCI vs 
standard care
MI size by CMR No change on MI size observed with 
either treatment
[57]
Hypothermia Erlinge D et al. 
(2014) CHILL-MI
120, 
multicenter 
RCT
Endovascular 
cooling vs 
standard care
MI size by CMR at 4 days No change in MI size observed [83]
Hyperoxemia Stone GW et al. 
(2009) AMIHOT-II
301, 
multicenter 
RCT
90 min IC SSO2 
to LAD vs 
standard care
MI size by SPECT Significantly reduced MI size 
More marked in LVEF <40% 
Noninferior rates of MACE
[86]
Regenerative therapies
BMC therapy De Jong R et al. 
(2015)
22, trials 
random-
effects meta-
analysis
BMC therapy in 
acute MI
LVEF, LV volumes, MI size, 
MACE
 Small significant reduction in MI size, 
with increased EF 
Benefit lost when restricted to CMR 
studies
[107]
Nowbar 
AN et al. (2014) 
DAMASCENE
49, trials 
meta-analysis
BMC therapy in 
acute MI
Trial discrepancies 
correlation with reported 
effect on effect size
Strong correlation between number 
of discrepancies and reported 
improvement in LVEF
[108]
BMC: Bone marrow cell; CA: Coronary artery; CABG: Coronary artery bypass grafting; CMR: Cardiac magnetic resonance; EF: Ejection fraction; HF: Heart failure; IC: Intracoronary; 
IPost: Ischemic postconditioning; iv.: Intravenous; LAD: Left anterior descending artery; LV: Left ventricle/ventricular; LVEF: Left ventricular ejection fraction; MACE: Major adverse 
cardiovascular event; MI: Myocardial infarction; MSI: Myocardial salvage index; PCI: Percutaneous coronary intervention; PPCI: Primary percutaneous coronary intervention; 
RCT: Randomized controlled trial; rIPC: Remote ischemic preconditioning; SC: Subcutaneous; SNP: Sodium nitroprusside; SPECT: Single-photon emission computed tomography; 
SSO
2
: Supersaturated oxygen; ST: ST-segment; STEMI: ST-elevation myocardial infarction. 
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during coronary artery bypass surgery. The 
expanded cell product was subsequently infused 
into the vessel supplying the ischemic territory. 
The investigators reported an improved global 
and regional left ventricular ejection fraction, 
increase in viable left ventricular mass by cardiac 
MRI and a reduction in scar size at 4 months, 
persisting out to 1 year. However, enthusiasm for 
these encouraging preliminary findings has been 
diminished by questions raised after publication 
that have resulted in an expression of concern 
and retraction of associated work [114,115]. More 
recently, the CADUCEUS trial [116] evaluated 
the feasibility and safety of cardiosphere-derived 
cells in acute myocardial infarction, randomiz-
ing 31 patients to intracoronary cell therapy or 
routine care. Technical difficulties and patient 
withdrawals resulted in only 17 patients being 
randomized to treatment and eight patients to 
control. While left ventricular ejection frac-
tion was unchanged at 1 year, the investigators 
observed a trend toward smaller scar size and 
an increase in viable myocardium in patients 
receiving cell therapy.
Optimal administration parameters
As is the case with the type and timing of 
administration of stem-cell products, optimal 
dosing and route of administration have yet to 
be established and this may be partly responsible 
for the inconsistency of the outcomes to date. 
The pharmacokinetics and dynamics of live 
cell-based therapies are fluid and complex so 
have yet to become sufficiently well under-
stood to provide optimal dosing and route of 
administration; there have been no studies to 
date that have simultaneously examined both 
dose and route [117]. The two most extensively 
investigated routes of administration have 
been endovascular (usually intracoronary) and 
intramyocardial (either surgically or transcath-
eter) with a tendency to see more encouraging 
results from the former route. Advances in tech-
nological approaches to cell harvest and admin-
istration coupled with evolving understanding 
of the complex biological interplay of stem-cell 
dynamics lend promise to the development of 
innovative cell therapy approaches in the future.
Growth factors & cytokines
The role of cytokine-mediated tissue growth at 
the peri-infarct zone and stimulation of endog-
enous myocardium in regulation of the response 
to injury is increasingly well recognized [118]. It 
is becoming increasingly apparent that paracrine 
actions of engrafted cells combined with growth 
factor-mediated signaling are likely to play a key 
role in the success of any biological therapy. 
Indeed, growth factors have received atten-
tion in their own right as potential therapeutic 
Trial Estimated 
enrollment
Design Intervention Primary outcome Estimated 
final 
completion
Ref.
RIC-STEMI 
(NCT02313961)
492 RCT Lower limb RIPC prior to ≥10 min prior 
to angioplasty vs no intervention
Cardiac mortality or HF 
admission at 1 year
May 2017  [132] 
CONDI-2/ 
ERIC-PPCI 
(NCT01857414/
NCT02342522)
4300/2000 Single/
double-
blinded RCT
4 × 5 min cycles limb RIPC prehospital 
vs no intervention/sham
Cardiac mortality or HF 
admission at 1 year
December 
2017/
December 
2019
 [133,134]
DANAMI-3 2000 Single-
blinded RCT
4 × 30 s cycles culprit vessel occlusion 
prior to stent deployment vs no 
intervention
All-cause mortality and 
heart failure
February 
2021
[39]
EMPRES 
(NCT01938235)
198 Double-
blinded RCT
iv. exenatide bolus (pre-PPCI) and 24 h 
infusion (post-PPCI) vs placebo
Infarct size: area at risk 
ratio (by CMR)
January 
2017
 [135]
CAPRI 
(NCT02390674)
68 Double-
blinded RCT
Single dose iv. cyclosporine prior to PCI 
vs placebo
Infarct size at 12 weeks 
(by CMR)
March 2018 [136]
DETO2X-AMI 
(NCT01787110)
6650 RCT Continuous inhaled oxygen (6 l/min) 
for 6–12 h from inclusion vs no 
intervention
All-cause mortality at 
1 year
September 
2017
[137]
NITRITE-AMI 80 Double-
blinded RCT
iv. sodium nitrite during PPCI vs 
placebo
Infarct size (by biomarker 
AUC) to 48 h
Awaited [60]
AUC: Area under the curve; CMR: Cardiac magnetic resonance; HF: Heart failure; iv.: Intravenous; PCI: Percutaneous coronary intervention; PPCI: Primary percutaneous coronary 
intervention; RCT: Randomized controlled trial; RIPC: Remote ischemic preconditioning.
Table 2. Major ongoing clinical trials of novel cardioprotective therapies.
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targets for myocardial regeneration following 
infarction [119]. While a detailed review of car-
diac growth factors can be found elsewhere [120], 
there have been a small number of clinical tri-
als in patients with acute myocardial infarction. 
Exogenous recombinant erythropoietin has been 
studied as a growth factor therapy in myocardial 
infarction and initially encouraging animal data 
lead to a series of clinical studies, although these 
failed to demonstrate any benefit [121]. Talan et al. 
explored the reasons for this failure in an animal 
model designed to specifically assess impact of 
the drug when given at varying time intervals 
and would more accurately reflect those of the 
clinical studies [121]. They found a reduction in 
infarct size of >50% in animals where erythro-
poietin was administered at the time of reperfu-
sion (2-h duration) but no effect on infarct size 
was seen with administration at 4 h or greater 
after reperfusion. This supports the theory that 
the therapeutic window for some therapies may 
be very narrow; a variable that further research 
in this field would need to recognize. In addition, 
animal models are well known to be limited in 
lacking the substrate for disease seen in humans, 
with absence of comorbidity and comparable 
pathophysiology. Other suggested contribut-
ing factors to the failure to translate to clinical 
research are insufficient sample size, lacking ani-
mal data on dose response, patient heterogeneity, 
variable routes of administration and forms of 
erythropoietin as well as potentially confound-
ing concurrent treatments [122]. To date, research 
into the role of growth factors has been largely 
preclinical and strategies utilizing growth fac-
tors alone are few. With further knowledge of 
the role of growth factors in myocardial injury, 
future options may explore their potential when 
co-administered with stem cell therapies.
Challenges facing biological therapies in 
acute myocardial infarction
Following a large number of studies in the field 
over the past two decades, the initial enthusi-
asm in biological therapies is moderated by the 
complexity of the molecular processes regulat-
ing cellular repair and regeneration. In general, 
there have been few safety concerns raised by 
the clinical studies carried out to date. Although 
tumor formation and ectopic tissue growth were 
encountered in animal studies [123], this has not 
been a major safety issue in clinical studies. 
Methodological and technical complications 
may account for much of the heterogeneity 
observed in the trials to date, as may small sam-
ple sizes. Larger, rigorously conducted and more 
specific trial data are needed to further improve 
our understanding of the optimal type of stem 
cell, dosage and route of administration as well 
as allay medium and longer term safety concerns. 
In addition, there is evidence that differences in 
intermolecular signaling pathways associated 
with advancing age may alter the pharmacoki-
netics and dynamics further indicating that 
patient selection is of key importance [124]. In 
summary, evidence of a robust, clinically sig-
nificant improvement in left ventricular systolic 
function following stem cell therapy in patients 
with acute myocardial infarction is limited.
Conclusion & future perspective
Encouraging preclinical data has often garnered 
great enthusiasm for development of novel ther-
apies in myocardial infarction, but translating 
these data in to the clinical arena has often 
proven challenging. The limitation of animal 
models of myocardial injury with the absence 
of substrate for cardiovascular disease, plaque 
rupture, thrombosis and microembolization 
is well established, and many clinical studies 
fail to reach statistical power in recruitment 
with diverse patient demographics and myo-
cardial injury profiles. The use of cardiac MRI 
as the gold standard of quantifying change in 
left ventricular ejection fraction is increasingly 
accepted, although it is conceivable that the 
more relevant end point is long-term clinical 
outcomes.
Understanding the physiology of cell signal-
ing in myocardial repair continues to evolve 
with the potential to progress some biologi-
cal regenerative therapies. Most cells in the 
body secrete small membrane-bound vesicles, 
exosomes, which can regulate intercellular 
microcommunication in both normal and path-
ological states [125]. Exosomes and microvesicles 
derived from stem cells contain various types 
of miRNAs, growth factors and cell-protec-
tion components believed to be fundamental 
to the cardioprotective potential of these cell 
therapies [125,126], suppressing apoptosis in the 
infarct zone as well as promoting neovascu-
larization and chemoattraction of cardiac pro-
genitor cells [127,128]. These exosome-secreted 
factors are cell-free and may offer cardiopro-
tective and regenerative potential without the 
need to harvest, expand and deliver stem cells 
to the heart. Ongoing research investigates 
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mRNAs as biomarkers for acute myocardial 
infarction (NCT02751060), looks to clarify 
their role in efficacy of antiplatelet therapy 
(NCT02071966) and aims to better under-
stand the role of mRNAs and microvesicles 
in acute myocardial infarction and left ven-
tricular remodeling (NCT01875484). Greater 
understanding in these areas may then lead to 
development of therapeutic strategies utiliz-
ing mRNAs and microvesicles for myocardial 
infarction.
Treatment with oral P2Y12 inhibitors is 
central to the current treatment of patients 
with acute myocardial infarction. While the 
benefit of P2Y12 inhibition has been largely 
attributed to their antiplatelet effect, there are 
emerging preclinical data to suggest a cardio-
protective role in the setting of ischemia-reper-
fusion injury [129,130]. Given the importance of 
timing in the delivery of treatments for acute 
myocardial infarction, rapid P2Y12 inhibition 
with intravenous administration of cangrelor, 
thus avoiding delays from gut absorption or 
metabolic conversion, may afford an opportu-
nity to maximize the cardioprotective poten-
tial of P2Y12 inhibition while retaining the 
antiplatelet benefits [130]. Future work may 
confirm these benefits in clinical practice. 
Cangrelor has been trialed in the PCI setting 
yielding mixed results for clinical end points. 
As yet there has been no trial of cangrelor in 
STEMI with primary end point of myocardial 
salvage [131].
Major progress has been made in the 
development and testing of a wide range of 
therapies to reduce the impact of reperfusion 
injury in acute myocardial infarction (sum-
marized in Table 1). Results of key trials are 
awaited with the hope of providing clarity with 
greater sample sizes and robust study design 
EXECUTivE SUMMARY
Ischemic conditioning
 ●  Utility of local ischemic conditioning is limited by its invasive nature.
 ●  Remote ischemic preconditioning has shown reduction in infarct size and improved long-term clinical outcomes; 
large-scale clinical trials are ongoing.
 ●  Ischemic postconditioning has yielded mixed results; large-scale trial is ongoing.
Pharmacological conditioning
 ●  Cyclosporine A and exenatide are undergoing clinical trial to clarify early negative clinical studies.
 ●  Promise shown by atrial natriuretic peptide is mitigated by concerns over increased in-hospital mortality.
 ●  A variety of innovative and novel agents are still undergoing clinical trial.
Mechanical & metabolic strategies
 ●  Cooling confers no significant improvement in left ventricular function overall, but may benefit anterior ST-segment 
elevation myocardial infarctions and reduce incidence of heart failure.
 ●  Ongoing clinical trial aims to clarify potential benefit from hyperoxemia.
 ●  The role of coronary sinus devices has yet to be established.
Biological therapies
 ●  A wide variety of stem cells have undergone preclinical and clinical trial.
 ●  No consensus is reached on optimal administration and dose regimes.
 ●  Realizing the potential of biological therapies will depend on continued understanding of intermolecular signaling 
pathways and cellular dynamics.
Future perspective
 ●  Significant progress has been made in pursuit of effective therapies against myocardial reperfusion injury.
 ●  Realization of the promise of cellular therapy may be achieved with a better understanding of the cellular mechanisms 
of myocardial repair.
 ●  Modification of gene expression may offer a more widely applicable alternative strategy for myocardial regeneration.
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(summarized in Table 2). These trials and other 
novel approaches offer hope to the next genera-
tion of clinical therapies in the battle against 
reperfusion injury.
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